#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ureteric cancer Prodromal Alzheimer's disease Medullary thyroid cancer Ovarian cancer stage III Partial lipodystrophy Haemophilia B with anti factor IX Depression Gastroenteropancreatic neuroendocrine tumour disease Hypochromic anaemia Retinoblastoma Philadelphia positive chronic myeloid leukaemia Chronic lymphocytic leukaemia recurrent Vulval cancer recurrent Acquired ATTR amyloidosis Mitochondrial DNA depletion More trials…

    Learn about Rare Diseases

    Wolfram syndrome – Treatment Congenital generalised lipodystrophy – Trials in Disease Burkitt’s lymphoma Idiopathic inflammatory myopathy – Treatment Medulloblastoma – Diagnostics Prader-Willi syndrome – Trials in Disease Haemophilia A with anti factor VIII Antisynthetase syndrome – Diagnostics Kearns-Sayre syndrome – Life with Disease Atypical teratoid/rhabdoid tumour of CNS – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Human Vaccinia Immunoglobulin Bay 3018250 Sodium ACT-1004-1239 Camphor ROC-101 HYDROCHLORIDE Farletuzumab Ecteribulin Onfekafusp Alfa Sodium Iodide AZD0120 Zanidatamab Ulipristal Acetate Tucidinostat LTX-002 SODIUM Infigratinib Xtmab-16 SIGVOTATUG VEDOTIN Benralizumab BROLUCIZUMAB Timolol More therapies…

    Learn about Your Condition

    Bladder cancer Brain stem glioma High-grade B-cell lymphoma Asthmatic crisis Migraine with aura Glomerulonephritis membranous Bone marrow failure Coma Primary biliary cholangitis Primary adrenal insufficiency Triple negative breast cancer Triple positive breast cancer Overweight Pulmonary tuberculosis Muscle spasticity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Belgium Czechia Denmark Italy The Netherlands Spain +1

  • Study of ipilimumab and nivolumab injected into tumors before surgery in patients with stage III melanoma that can be removed by surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    France

  • Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    France Germany Italy Poland Romania Spain +1

  • Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • GSK5733584
    • Bevacizumab
    • Dostarlimab
    Belgium Denmark Finland France Germany Greece +6

  • Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • OSIMERTINIB MESYLATE
    • Pembrolizumab
    France Italy The Netherlands Spain

  • Study of ETX-19477 for Patients with Advanced Solid Tumors After Standard Treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • ETX-19477
    France Italy Spain
Previous Page
1 2 3 4 5 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!